Article Text

other Versions

Download PDFPDF
Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer
  1. Amanda Landers1,
  2. Wendy Muircroft2 and
  3. Helen Brown1
  1. 1Hospice Palliative Care Service, Nurse Maude Association, Christchurch, New Zealand
  2. 2Department of Palliative Care, Queen Elizabeth Hospital, Adelaide, South Australia, Australia
  1. Correspondence to Dr Amanda Landers, Hospice Palliative Care Service, Nurse Maude Association, P O Box 36-126, Christchurch 8146, New Zealand; Amanda.Landers{at}


Purpose The diagnosis of metastatic pancreatic cancer (PC) carries a poor prognosis. PC is associated with weight loss and malabsorption in high rates secondary to pancreatic exocrine insufficiency. UK and USA guidelines exist recommending the empiric use of pancreatic enzyme replacement therapy (PERT) for quality of life in these patients. The aim of this study is to review the use of PERT in patients with metastatic PC referred to a specialist palliative care service.

Methods Retrospective observational study of patients referred to the service between January 2010 and July 2012 with a diagnosis of PC. Information about PERT use, tumour site and frequency of symptoms was collected.

Results 129 patients were referred, with a higher number in the eighth decade. Only 21% of this study group were prescribed PERT. Over 70% of patients had symptoms that could be attributable to malabsorption, mainly abdominal pain. Other symptoms such as bloating, wind and steatorrhoea were also common.

Conclusions Guidelines recommending empiric treatment of PERT in patients with metastatic PC are not currently being utilised.

  • Supportive care
  • Pharmacology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.